RI-1

• Description :

  RI-1 is a RAD51 inhibitor, with IC50s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  RAD51

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/RI-1.html

• Concentration :

  10mM

• Purity :

  99.83

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles :

  O=C(C(N1CCOCC1)=C2Cl)N(C3=CC=C(Cl)C(Cl)=C3)C2=O

• Molecular Formula :

  C14H11Cl3N2O3

• Molecular Weight :

  361.61

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Budke B, et, al. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res. 2012 Aug;40 (15) :7347-57.|[2]Shi Y, et, al. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. Neoplasia. 2019 Jun;21 (6) :533-544.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [415713-60-9]